Follow the Money: Pharma companies spend big on Nevada lawmakers
Between a heavy union presence and immense pressure from industry players, next week’s hearing on a major pharmaceutical regulatory measure, including price controls on diabetes medicine, promises to be one of the hardest fought battles of the 2017 session.
Go here for the full story.